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ABSTRACT
Estrogen receptors (ERs), which mediate the
proliferative action of estrogens in breast cancer
cells, are ligand-dependent transcription factors
that regulate expression of their primary target
genes through several mechanisms. In addition to
direct binding to cognate DNA sequences, ERs can
be recruited to DNA through other transcription
factors (tethering), or affect gene transcription
through modulation of signaling cascades by
non-genomic mechanisms of action. To better
characterize the mechanisms of gene regulation by
estrogens, we have identified more than 700 puta-
tive primary and about 1300 putative secondary
target genes of estradiol in MCF-7 cells through
microarray analysis performed in the presence or
absence of the translation inhibitor cycloheximide.
Although siRNA-mediated inhibition of ERa expres-
sion antagonized the effects of estradiol on up- and
down-regulated primary target genes, estrogen
response elements (EREs) were enriched only in
the vicinity of up-regulated genes. Binding sites for
several other transcription factors, including pro-
teins known to tether ERa, were enriched in up-
and/or down-regulated primary targets. Secondary
estrogen targets were particularly enriched in sites
for E2F family members, several of which were
transcriptionally regulated by estradiol, consistent
with a major role of these factors in mediating the
effects of estrogens on gene expression and cellular
growth.
INTRODUCTION
The pleiotropic eﬀects of estrogens in its numerous target
tissues, including the reproductive, skeletal, cardiovascular
and central nervous systems (1–5) are mediated in large
part via ERs (6), which are members of the superfamily of
nuclear receptors and function as hormone-dependent
transcription factors (7–9). ERs bind DNA directly
through their central, conserved DNA-binding domains
composed of two zinc ﬁngers of the C4 type (10,11).
Cognate DNA-binding motifs, also called estrogen
response elements (EREs), have been characterized in
estrogen-responsive promoters (12–15). Consensus EREs
derived by compiling natural response elements are 15bp
palindromes of PuGGTCA motifs with a 3bp spacer and
correspond to the highest aﬃnity binding sites for ERs
in vitro (16,17). However, natural response elements often
deviate from the consensus at one or several positions
(14,15). Both estrogen receptors share similar in vitro
DNA-binding patterns (18), but their transcriptional
activation properties diﬀer (6,19,20), possibly due to
diﬀerential recruitment of transcriptional coactivator
complexes responsible for histone acetylation, chromatin
remodeling and enhanced recruitment of the basal
transcription machinery (21–27). ERa is thought to
mediate the proliferative eﬀects of estrogens in breast
cancer cells. Indeed, its expression is preserved or increased
in two-thirds of breast tumors, correlating with sensitivity
of tumors to antiestrogenic treatment (3–5). On the other
hand, the expression of ERb, which was reported to play
a role in terminal diﬀerentiation of breast epithelial cells
(28), appears to be reduced during tumorigenesis (29,30).
In addition to mediating gene regulation through direct
binding to DNA, ERs can regulate gene expression
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tion factors (tethering). Several transcription factors were
shown to mediate positive or negative transcriptional
regulation by ERs in the absence of EREs, including AP1,
Sp1, NF-kB (15,31–33). In addition, interference between
estrogen signaling and other intracellular signaling
pathways including the MAPK and PI3K pathways have
been widely reported and may result from interactions
between ERs and components of these signaling cascades
(15,34–38). Finally, it has recently been suggested that
estrogens may act also through a membrane receptor
member of the GPCR family, GPR30, although the
importance of these receptors in breast tumorigenesis
remains to be established (39–43). These so-called non-
genomic mechanisms of action can lead to rapid kinase-
mediated activation of transcription factors and thus
modulate gene expression in response to estrogens.
Primary gene regulation by estrogen (i.e. genes regulated
in the absence of de novo protein synthesis) can therefore
result from at least three diﬀerent mechanisms, including
tethering and non-genomic action in addition to classical,
ERE-mediated transcriptional regulation.
Better understanding of the mechanisms of action of
estrogens in breast tumorigenesis necessitates large-scale
identiﬁcation of estrogen target genes and comprehensive
analysis of the mechanisms of target gene regulation to
assess the contribution of diﬀerent regulatory mechanisms
and speciﬁc targets to the proliferative eﬀects of estrogens.
Genome-wide microarray analysis of estradiol (E2) target
genes has been performed in ERa-positive breast cancer
cell lines such as MCF-7, T47D and ZR75 cells, leading
to the identiﬁcation of a large number of target genes
(44–50). It is however not always clear to which degree
target identiﬁcation is aﬀected by cell culture conditions,
choice of microarray platform and statistical analysis
tools. In addition, few studies have used conditions that
distinguish between primary and secondary target genes.
This may explain why enrichment in EREs in estrogen
target genes identiﬁed through microarray analysis was
not reported in most studies. On the other hand, the
promoter regions of 89 E2 target genes regulated in the
presence of CHX in T47D cells were found enriched in
EREs (46). However, the number of primary E2 target
genes identiﬁed in that study remains low and the question
of how far from the transcriptional start sites of primary
target genes enrichment in EREs can be observed remains
open given the relatively narrow window used. High-
aﬃnity EREs located distally from the start sites of
estrogen target genes are functional ER-binding sites
in chromatin immunoprecipitation (ChIP) experiments
(50,51). Although the role of ERs bound to distal sites
in transcriptional regulation remains to be systemati-
cally analyzed, chromatin conformation capture assays
revealed that ERa-bound chromatin regions can act at
large distances from regulated genes (48,52). In addition
to EREs, binding sites for several other transcription
factors were enriched in ERa-bound ChIP fragments,
suggesting roles for these factors in ERa tethering (48).
In order to better study the mechanisms of target gene
regulation by estrogens, we aimed to discriminate between
primary and secondary E2 target genes in MCF-7 cells
through microarray analysis of gene expression patterns in
response to E2 either in the presence or the absence of the
protein synthesis inhibitor cycloheximide. We veriﬁed the
validity of this approach by demonstrating enrichment in
EREs in primary, but not secondary up-regulated genes,
and identiﬁed other transcription factors involved in the
regulation of primary and/or secondary estrogen targets.
Our results are discussed in the context of previous studies
based on large-scale microarray analysis or genome-wide
ChIP-on-chip mapping of ERa-associated chromatin
regions.
MATERIALS AND METHODS
Cellculture andtreatments
MCF-7 breast carcinoma cells were maintained in
a-minimal Eagle’s medium (a-MEM) (Wisent, St-Bruno,
QC, Canada) supplemented with 10% fetal bovine serum
(FBS) (Sigma-Aldrich, Oakville, ON, Canada). Three days
before experiments, cells were switched to phenol red-free
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Wisent)
containing 10% charcoal-treated FBS, 1% sodium pyru-
vate (Wisent), 1% penicillin/streptomycin (Wisent) and
1% L-glutamine (Wisent). Cells were seeded in 10cm plates
at a density such that near-conﬂuency is obtained at the
end of the treatment. The day before hormonal stimula-
tion, the medium was changed to phenol red-free DMEM
supplemented with 0.5% charcoal-treated FBS. Pre-
treatments with cycloheximide (10mg/ml, Sigma) were
initiated 1h before hormonal treatment with 17b-estradiol
(E2, 25nM, Sigma), ICI 182,780 (ICI, 100nM, Sigma)
or vehicle (0.1% ethanol) for variable periods of time as
indicated in ﬁgure legends. Selected siGenome siRNAs
(Dharmacon, Chicago, IL, USA) were transfected using
siLentFect lipid reagent according to the instruction of
the manufacturer (Bio-Rad Laboratories, Hercules, CA,
USA). Medium was changed 24h after transfection with
fresh phenol red-free DMEM supplemented with 0.5%
charcoal-treated FBS and hormonal treatments were
initiated 48h after transfection. Cells were harvested 24h
after (i.e. 72h after siRNA transfection).
Westernanalysis
Whole cell extracts were prepared as described previously
(53) using antibodies directed against ERa (mouse mono-
clonal B10 antibody, a kind gift from Prof. P. Chambon)
or against b-actin mouse monoclonal antibody (AC-15,
Sigma Diagnostics).
Growthassays
MCF-7 breast cancer cells were seeded to low density
and treated every 2–3 days with vehicle (0, 0.1% ethanol),
17b-estradiol (E2, 25nM) or ICI 182-720 (ICI, 100nM) in
5% charcoal-stripped FBS. Protein concentrations were
measured after 9 days as previously described (54). When
siRNA were used, cells were re-plated 24h after transfec-
tion at low density and treated twice over a 5-day period
with vehicle (0, 0.1% ethanol), 17b-estradiol (E2, 25nM)
or ICI 182-720 (ICI, 100nM) prior to quantiﬁcation of
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representative of two to three independent experiments
performed with duplicate samples.
Cellcycle analysis
MCF-7 cells were transfected as previously described.
After 24h, medium was changed for phenol red-free
DMEM supplemented with 0.5% charcoal-treated FBS
and 24h later, stimulated with either vehicle (0, 0.1%
ethanol) or estradiol (E2, 25nM) for a last 24h. Cell cycle
values were obtained after ethanol ﬁxation and propidium
iodide staining followed by data acquisition on a FACS
‘BD LSR II’ and analysis using the ModFit LT cell cycle
software. Experiments were performed at least twice with
duplicate samples.
RNA purification and DNA microarrays
After treatment of MCF-7 cells with estradiol or vehicle
in the presence or absence of cycloheximide, medium
was completely removed and cells were collected in 1ml
of TRI-Reagent (Sigma). Total RNA was extracted
as recommended by the manufacturer and further
puriﬁed with RNeasy MinElute Cleanup Kit (QIAgen,
Mississauga, ON, Canada). cRNA synthesis from total
RNA, labeling and hybridization to Aﬀymetrix HG-U133
2.0 Plus gene chips were performed at the Genome Quebec
and McGill University Innovation Center using standard
protocols (http://www.genomequebec.mcgill.ca/). A total
of 16 chips were hybridized, analyzing quadruplicate
samples for each of the four treatment conditions.
The microarray analysis was performed with the
aﬀylmGUI Bioconductor package (55) after normaliza-
tion of probe-level data with RMA (56). Genes deemed
signiﬁcantly regulated were those with 1.4-fold change
between vehicle and E2 treatments, average log2-
expression levels greater than 5 across all samples
(A-value) and a P-value for moderated t-statistics (57)
smaller than 0.01. Regulated genes were ranked according
to |fold|
A
(1 – P-value). The 2144 regulated genes were
classiﬁed into diﬀerent subsets as follows. UP-regulated:
1214, DOWN-regulated: 955, UP CHX: 858, UP only
CHX: 670, UP+and CHX: 188, UP only +CHX:
356, UP +CHX: 544, DOWN CHX: 838, DOWN only
CHX: 719, DOWN + and CHX: 119, DOWN only
+CHX: 117, DOWN +CHX: 236. The microarray data
is accessible through the GEO accession number
GSE8597.
Screeningfor transcription factorbinding sites
The reference human genome sequences (hg17, May 2004)
were downloaded from the UCSC Genome Browser
database (58). Genomic sequences in windows centered
around the transcription start sites (TSS) of all annotated
gene in the RefSeq Genes track (59) were extracted
from the genome. These sequences were screened with
299 matrices for transcription factor binding sites using
a base score cutoﬀ of 65% and 5% increments. The
program used for screening implements the formulas
described by Wasserman and Sandelin (60); other
programs developed for genome-wide screen of nuclear
receptor response elements (51,61,62) were used to
calculate the distance from the TSS and identify binding
sites within transposable elements or regions bound in
ChIP-on-chip experiments. The majority of matrices used
was from the public version of TRANSFAC (63) or
represented variation of TRANSFAC matrices (i.e. E2F
matrix M00516 where only the portion matching
TTTSGCGC was used). Selected matrices were compiled
from the literature including matrices for estrogen
response elements (51,64,65) and RXR/RAR (66).
Searches were also performed with the same sequences
from which transposable elements were removed, or with
only sequences present in conserved regions, as described
in the ‘PhastCons Conserved Elements’ track from the
UCSC (67), within the same windows. For each transcrip-
tion factor, four cutoﬀs were chosen with frequencies in
all gene promoters closest to those of EREs (70%: 0.32
ERE/gene, 75%: 0.16 ERE/gene, 80%: 0.06 ERE/gene,
85%: 0.02 ERE/gene). Cutoﬀs were required to be
between 2 sites/gene and 0.01 site/gene to avoid overly
abundant sites or rare sites. Z-scores and P-values were
determined for each of the selected cutoﬀs to assess the
statistical signiﬁcance of the observed enrichment in
promoters of diﬀerent sets of regulated genes versus
those of all annotated genes. The Z-scores and P-values
were calculated with programs adapted from oPOSSUM
perl application programming interface (API) using the
cutoﬀ recommended by the authors (68). The P-value
indicates if the proportion of genes is greater than
would be expected by chance in a Fisher exact test.
The Z-score evaluates the signiﬁcance of the rate of
occurrence of sites in the test set of regulated genes versus
the expected rate estimated from the background set
composed of all genes in the genome using a binomial
distribution model. Stars indicate the signiﬁcance of both
parameters (Z-scores >10, P-value <0.01). The ERa
ChIP-on-chip dataset (50) was downloaded from the
Brown Lab website (http://research.dfci.harvard.edu/
brownlab/datasets/index.php) and the E2F1 ChIP-
on-chip dataset (69) was downloaded from the NCBI
(GSE5175).
Gene expression quantification
Total RNAs were extracted as described earlier and
aliquots of 2mg were reverse transcribed using the
RevertAid H ﬁrst minus strand cDNA synthesis kit
(MBI Fermentas, Burlington, ON, Canada) as recom-
mended by the manufacturer. Reverse transcription
products were diluted 10 times in pure water prior to
real-time quantitative PCR. Gene expression levels were
determined using primer and probe sets from the
Universal Probe Library (https://www.roche-applied-
science.com). PCR reactions were performed in 384-well
plates using 2ml of cDNA sample, 5ml of TaqMan PCR
Master Mix (Applied Biosystems, CA, USA), 2mMo f
each primer (sequences available upon request) and 1mM
of the Universal TaqMan probe in a total volume of 10ml.
The ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems) was used to detect ampliﬁcation
levels and was programmed for an initial step at 958C for
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608C. All reactions were run in duplicates or triplicates
and average values were calculated. Quantiﬁcation was
performed with at least two independent experiments. The
housekeeping RPLP0 (ribosomal protein, large, P0) gene
was used as endogenous control. Relative expression levels
of target genes and SD values were determined using the
CT method.
Chromatin immunoprecipitation
For chromatin immunoprecipitation (ChIP) assays,
chromatin was cross-linked by treating cells with 1.5%
formaldehyde for 10min at room temperature and
fragmented by sonication as previously reported (51,52),
yielding fragments of average size 400bp. Immuno-
precipitation were conducted as previously described
(51,52). Antibodies against a C-terminal epitope of
hERa (SC-543) and against b-actin (SC-8432) were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). Detailed conditions for immunopre-
cipitation, PCR ampliﬁcation and primer sequences
(synthesized by Sigma Genosis) used in ChIP assays are
available upon request. Chromatin immunoprecipitation
experiments were performed twice with similar results.
A representative set of results is shown.
RESULTS
Identification ofprimary target genesof estrogen
receptor alphainMCF-7 cells
MCF-7 cells are one of the most widely used cell models to
study estrogen signaling as they are strongly growth-
stimulated by 17b-estradiol (E2) in vitro (Figure 1A) and
in xenograft experiments (70), and express high levels of
estrogen receptor alpha (ERa). Transfection of siRNAs
directed against ERa, but not GAPDH or Luciferase
(LUC), strongly suppressed MCF-7 cell growth
(Figure 1B), indicating that ERa expression levels are
rate limiting for growth of these cells. In the absence of
E2, MCF-7 cells cultured in 0.5% charcoal-treated serum
were mostly arrested in the G0–G1 phase (>80%), while
addition of E2 for 24h augmented signiﬁcantly the
proportion of cells in S phase (Figure 1C). On the other
hand, transfection of siRNAs against ERa reduced this
proportion both under basal and induced conditions.
Thus, it is likely that genes regulated by estrogens
under these conditions include a large proportion of cell
cycle-regulated genes, some of which may not be primarily
regulated by estrogens. Indeed, E2 treatment leads to
regulation of transcription factors, cofactors and signaling
proteins, which ampliﬁes the genomic eﬀects of estrogens
but complicates the analysis of the mechanisms of target
gene regulation.
To identify primary estrogen target genes in MCF-7
cells, we performed treatments with E2 for 24h with or
without pre-treatment of cells with the protein synthesis
inhibitor cycloheximide (CHX). Gene expression patterns
were analyzed using Aﬀymetrix GeneChips HG-U133 2.0
Plus chips representing over 47000 human transcripts.
Diﬀerential expression was assessed as the ratio between
the average of the four replicates in the presence of
estrogen versus its absence, either in the presence of CHX
or in its absence. A cutoﬀ of 1.4-fold change in expression
was applied, based on the observed regulation of known
ER targets such as TFF1 under these conditions. A total
of 2144 signiﬁcantly regulated genes were identiﬁed
and ranked according to their combined P-value, fold-
regulation and intensity of expression (see the lists of the
top 100 genes regulated in the absence or presence of CHX
in Table 1). There was a signiﬁcant overlap in regulated
genes with other microarray studies, which was optimal
when using similar ﬁltering parameters for the analysis
of all the datasets [922/2144 with Carroll et al. (50) and
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Figure 1. Role of ERa in mediating the eﬀect of estradiol in MCF-7
breast cancer cells. (A) MCF-7 breast cancer cells were treated every 2
days with vehicle (0, 0.1% ethanol), 17b-estradiol (E2, 25nM) or ICI
182 720 (ICI, 100nM) and protein concentrations were measured after
9 days. (B) Proliferation assays of MCF-7 transfected without (0) or
with siRNA against ERa, GAPDH or Luciferase (LUC). Treatments
were initiated 24h after transfection and protein concentrations were
measured 6 days post-transfection. Inset: western blot analysis of ERa
and b-actin expression levels in cells transfected with siRNAs directed
against ERa or in control cells (T: transfection control). (C) Cell cycle
analysis performed with cells transfected or not with siRNAs for 72h
and stimulated with vehicle or hormone during the last 24h.
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Without CHX With CHX
RANK Symbol Fold A P-value Validated RANK Symbol Fold A P-value Validated
1 MYBL1 13.85 7.23 4.07E10 yes 1 KRT13 15.90 6.81 3.46E13 –
2 FLJ30058 14.85 5.66 5.16E12 –2 LOC283551 15.04 5.81 3.26E13 –
3 PKIB 7.09 10.22 5.01E13 yes 3 FLJ10847 11.11 5.12 1.46E16 –
4 SYTL4 5.79 7.86 4.39E10 –4 CYP26B1 7.46 7.05 5.91E12 yes (DNS)
5 SGK3 5.99 6.93 2.40E08 –5 SGK3 6.89 6.93 1.86E08 yes (DNS)
6 UGT2B15 6.19 6.45 3.14E09 –6 FLJ30058 7.60 5.66 4.93E11 –
7 PCP4 5.03 7.28 1.14E11 –7 SLC26A2 5.40 7.85 1.22E11 yes
8 TMPRSS3 5.42 6.72 9.36E12 –8 MYBL1 5.27 7.23 3.45E07 yes
9 MCM10 4.96 6.97 8.87E11 yes 9 RET 4.68 8.12 5.30E12 yes
10 RRM2 3.44 10.03 9.07E12 – 10 C8orf46 6.10 5.85 5.78E11 –
11 MLF1IP 3.89 8.76 1.56E11 – 11 RBP7 4.53 7.75 5.91E12 yes
12 ATAD2 3.47 9.45 6.83E10 –1 2 RBM24 4.95 7.02 7.32E12 –
13 DCC1 4.78 6.64 1.34E10 – 13 TMEM64 3.26 10.13 3.50E10 –
14 UHRF1 3.49 9.04 2.63E11 –1 4 CA12 3.43 9.42 5.66E13 yes
15 TK1 3.58 8.80 4.97E11 – 15 XBP1 3.13 10.27 4.50E11 yes
16 IL17RB 4.24 7.38 1.87E11 – 16 KCNK6 4.33 7.32 5.30E12 –
17 GREB1 3.14 9.85 5.09E11 yes 17 DEPDC6 3.75 8.35 8.37E12 –
18 PBK 3.93 7.85 8.91E10 – 18 IL17RB 4.08 7.33 2.12E11 –
19 BRIP1 3.08 9.84 2.39E07 – 19 OACT1 4.68 6.32 8.37E12 –
20 TYMS 3.28 9.18 5.91E11 – 20 CDH26 4.96 5.82 1.26E07 yes
21 DTL 4.49 6.66 4.39E10 – 21 CALCR 2.82 9.97 3.18E11 yes
22 EXO1 4.54 6.58 9.07E12 – 22 CELSR2 3.22 8.66 1.41E12 yes (DNS)
23 LOC221981 2.89 10.32 3.88E10 – 23 KRT4 3.91 7.01 1.53E08 yes
24 ANLN 3.34 8.90 8.05E09 – 24 PAPSS2 2.60 10.44 1.03E10 –
25 CCNE2 3.69 7.89 1.95E09 – 25 DSCAM 4.12 6.57 1.05E10 yes
26 CDC2 3.10 9.34 1.98E10 – 26 CARD10 4.04 6.59 1.59E11 yes (DNS)
27 AREG 3.32 8.69 2.35E11 yes 27 TPD52L1 2.55 10.14 5.69E11 –
28 RLN2 3.38 8.36 1.11E09 –2 8 CXCL12 3.62 6.99 8.64E10 –
29 MGP 3.79 7.37 4.63E11 – 29 LRIG1 3.82 6.54 5.91E12 yes
30 CXCL12 3.97 6.99 2.28E10 –3 0 RLN2 2.97 8.36 9.91E09 –
31 CHEK1 4.18 6.61 7.62E09 Yes (DNS) 31 ANKH 3.77 6.58 3.18E11 –
32 TOP2A 2.97 9.24 1.60E09 – 32 C14orf139 4.71 5.08 5.30E12 –
33 KIAA0101 2.63 10.41 1.38E10 – 33 C22orf19 2.90 8.23 2.37E11 –
34 RERG 3.33 8.15 9.07E12 –3 4 RP13-360B22.2 2.88 8.21 4.39E11 –
35 CYP26B1 3.85 7.05 6.70E10 yes 35 PXK 3.59 6.53 4.33E09 –
36 FSHPRH1 4.41 6.15 1.30E10 – 36 TUBA3 2.18 10.62 3.25E09 –
37 Pfs2 3.31 8.19 1.24E10 –3 7 MYB 2.62 8.66 5.91E12 yes
38 BRCA1 4.15 6.49 2.17E10 yes 38 C2orf23 3.04 7.43 5.91E12 –
39 CDKN3 2.90 9.28 1.33E09 – 39 UGT2B15 3.47 6.45 1.20E06 –
40 SFXN2 3.15 8.51 1.87E11 – 40 STC2 2.38 9.31 2.50E11 –
41 FLJ10719 3.69 7.25 1.60E09 – 41 P4HA2 2.62 8.29 5.59E11 –
42 CDC45L 3.82 6.86 1.14E11 yes 42 FLJ33718 2.73 7.92 1.03E10 –
43 PCNA 2.61 10.01 2.54E10 – 43 SMOX 3.20 6.72 2.81E11 –
44 CDH2 2.68 9.71 2.48E11 – 44 GPSM1 2.62 8.13 8.27E11 –
45 HEY2 3.46 7.51 2.48E11 –4 5 GREB1 2.15 9.85 1.62E08 yes
46 C10orf3 3.47 7.47 4.06E08 – 46 ITGA2 3.52 5.99 9.34E10 –
47 G30 2.74 9.40 1.21E11 – 47 FKBP4 1.90 10.90 2.01E09 –
48 GMNN 2.99 8.60 4.97E11 – 48 PKIB 2.00 10.22 1.22E07 yes
49 DEPDC6 3.05 8.35 6.81E11 –4 9 RAB27B 2.33 8.70 1.78E08 yes
50 CDC6 4.21 6.05 3.51E09 –5 0 KIAA1324 2.10 9.64 1.79E10 –
51 KLK11 2.74 9.28 2.48E11 –5 1 PCP4 2.78 7.28 4.14E09 –
52 FKSG14 4.34 5.82 1.10E08 – 52 UGCG 2.64 7.56 2.44E08 –
53 FHL1 2.93 8.63 4.39E10 – 53 RHOD 2.03 9.83 1.11E09 –
54 MAD2L1 3.14 8.04 6.55E09 – 54 ANXA9 2.00 9.92 2.47E09 –
55 PRIM1 3.22 7.84 4.63E11 –5 5 WFS1 2.43 8.16 7.02E10 –
56 GLA 2.78 9.06 1.14E11 –5 6 SLC29A1 3.22 6.14 2.05E10 –
57 CDT1 2.98 8.42 1.49E11 – 57 SOX9 2.47 8.02 1.70E09 –
58 MYBL2 3.15 7.89 9.57E11 yes 58 PLEKHH1 2.88 6.87 8.27E11 –
59 BCMP11 3.27 7.57 2.37E09 –5 9 SH2BP1 2.33 8.45 9.91E09 yes
60 HCAP-G 3.54 6.99 8.72E10 – 60 WISP2 2.04 9.65 8.39E10 yes
61 RAD51AP1 3.97 6.20 3.32E08 – 61 SLC9A3R1 1.76 11.14 7.70E09 –
62 CDH26 4.20 5.82 2.32E07 yes 62 RERG 2.41 8.15 2.90E10 Yes (DNS)
63 ZNF367 3.30 7.33 1.38E10 – 63 IGFBP4 1.97 9.88 7.97E09 yes
64 CDCA5 3.06 7.91 4.85E11 – 64 CD33L3 2.82 6.89 4.17E10 –
65 ASF1B 2.97 8.10 1.38E11 – 65 RNF150 3.57 5.41 3.97E10 –
66 UBE2C 2.38 10.08 4.02E10 – 66 TGM2 2.97 6.48 1.85E08 –
(continued)
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analysis by a Fisher exact test indicates that all overlaps
between two datasets are signiﬁcant (P-value lower than
2.2E16 for each pair of microarrays); in addition, much
smaller overlaps are found in random simulations
performed 1 million times (percentages or number of
genes identiﬁed by a star in Figure 2A). The large majority
(>90%) of genes in the overlapping sets were regulated
similarly in pairwise comparisons (see legend of
Figure 2A). A total of 203 target genes were identiﬁed as
estrogen target genes in all three studies. This partial
overlap may reﬂect diﬀerences in experimental conditions
(e.g. time of treatment, culture medium) or in the type of
microarrays (Aﬀymetrix U133A versus U133 Plus 2.0).
Regulated genes included nearly equivalent numbers of
up- and down-regulated genes in the absence of CHX (858
up-regulated and 838 down-regulated genes, Figure 2B),
but more than twice as many up- versus down-regulated
genes in the presence of CHX (544 up-regulated and 236
down-regulated genes, Figure 2B). Only 25 genes had
opposite regulation in the absence or presence of CHX.
The proportion of genes regulated in the absence (78%)
versus the presence (35%) of CHX in this study was
similar when considering only genes that were not
identiﬁed as E2 targets in the two previous large-scale
studies in MCF-7 cells (50,71). This indicates that
treatment with the protein synthesis inhibitor is unlikely
to account for the partial overlap with these studies.
Moreover, although it is possible that CHX treatment
may mask regulation of some target genes, CHX
treatment did not have a pronounced global eﬀect on
expression of the group of genes induced only in the
absence of CHX (Supplementary Figure 1). Regulation of
target gene expression by E2 in the absence or presence of
CHX was conﬁrmed using Q-PCR for 41 putative primary
and 22 putative secondary target genes (Supplementary
Figure 2).
Surprisingly, the overlap between genes regulated in the
presence and absence of CHX was only partial (35% for
up-, 50% for down-regulated genes). Regulation of gene
expression only in the presence of CHX may be due
to several factors, including regulation below the cutoﬀ
Table 1. Continued
Without CHX With CHX
RANK Symbol Fold A P-value Validated RANK Symbol Fold A P-value Validated
67 UBE2T 2.63 9.11 2.48E11 – 67 SOX2 2.21 8.69 1.83E08 –
68 KNTC2 3.32 7.16 2.71E07 – 68 SCARB1 2.27 8.44 1.86E10 –
69 MELK 3.07 7.70 1.19E10 – 69 ABHD2 2.44 7.85 1.10E09 –
70 SPBC25 4.36 5.42 3.51E09 – 70 BLVRB 1.97 9.71 8.39E10 –
71 LOC440687 2.90 8.12 3.59E09 – 71 IDH1 2.00 9.54 2.09E10 yes (DNS)
72 E2F8 3.33 7.09 9.46E10 yes 72 SYNE2 2.31 8.25 9.16E09 –
73 KIAA1212 2.34 10.05 3.07E11 – 73 SYTL5 1.98 9.55 3.26E09 yes
74 RAB31 2.77 8.48 3.01E11 – 74 COL18A1 2.34 8.02 2.34E10 –
75 FANCD2 3.41 6.87 1.02E09 – 75 ISG20 2.15 8.65 2.53E08 –
76 KIF11 3.32 7.04 1.33E07 – 76 SYTL4 2.36 7.86 1.06E05 –
77 BRCA2 3.90 5.99 1.48E09 yes 77 SEPT9 1.72 10.71 1.81E08 –
78 MCM2 2.64 8.84 7.18E10 yes 78 CCND1 1.83 9.95 2.55E07 yes
79 HELLS 3.49 6.67 7.95E11 – 79 SLC35E2 1.87 9.75 5.74E09 –
80 MCM6 2.37 9.79 1.10E09 yes 80 SLC25A24 1.72 10.58 2.16E07 –
81 TTK 3.19 7.26 8.41E09 – 81 MYO1B 1.69 10.73 6.67E08 yes (DNS)
82 E2F7 3.94 5.88 6.39E09 yes 82 FER1L3 1.63 11.04 9.86E08 –
83 PRC1 2.42 9.55 4.49E10 – 83 ADAMTS19 2.08 8.64 2.51E10 –
84 RET 2.84 8.12 4.49E10 yes 84 ARHGAP26 2.84 6.29 8.64E10 –
85 PSF1 2.77 8.31 2.48E11 – 85 KLF4 1.61 10.94 1.69E07 –
86 XBP1 2.24 10.27 2.59E09 yes 86 TPBG 1.55 11.39 4.87E07 –
87 PLAC1 4.21 5.42 2.06E11 – 87 HIPK2 2.13 8.25 2.16E09 –
88 LOC441168 2.11 10.79 2.54E10 – 88 NPY1R 2.01 8.71 2.56E08 –
89 CDCA1 3.51 6.46 1.78E07 – 89 EFEMP1 1.92 9.09 1.68E08 –
90 HIST1H4C 2.29 9.88 6.50E09 – 90 C6orf141 1.81 9.67 1.85E08 –
91 RAD51 3.78 6.00 2.06E11 – 91 TST 1.80 9.72 1.25E08 –
92 KIF23 2.89 7.84 2.78E07 – 92 MCM6 1.77 9.79 6.11E07 yes
93 PLK4 3.32 6.79 9.88E09 yes (DNS) 93 GLA 1.90 9.06 4.33E09 –
94 FEN1 2.63 8.56 1.04E10 yes 94 THRAP4 2.51 6.84 6.29E09 –
95 EGR3 3.95 5.70 1.92E09 yes (DNS) 95 RBBP8 2.06 8.34 4.62E07 yes (DNS)
96 DUT 2.36 9.52 4.49E10 – 96 FLJ20366 2.61 6.57 6.62E09 –
97 OFCC1 2.02 11.10 5.46E10 – 97 LAPTM4A 1.47 11.64 7.83E07 –
98 POLE2 3.32 6.74 3.00E10 yes 98 SFXN2 2.01 8.51 1.39E08 –
99 RNASEH2A 2.60 8.61 4.82E10 – 99 PGR 3.21 5.34 1.48E07 yes
100 DHFR 2.86 7.78 3.23E09 – 100 BRP44L 2.10 8.14 5.41E09 –
Genes were ranked based on a combination of three parameters, fold-change between E2 and vehicle treatments, amplitude of array signals across all
conditions and P-value based on moderated t-statistics. Genes in bold are those found signiﬁcantly regulated both in the absence and presence of
cycloheximide (CHX). Validated genes are those for which regulation was observed in Q-PCR with at least two independent experiments (see also
Figures 3–5 and Supplementary Figure 2; DNS, data not shown; –, not tested).
Nucleic Acids Research, 2008, Vol. 36, No. 1 81and/or lack of detection of transcripts in the CHX
category, or suppression of negative feedback mechanisms
on ER-mediated gene expression by CHX treatment.
Several well-known estrogen target genes were represented
in the set regulated only in the presence of CHX, including
CCND1, IGFBP4, C3 and MYC. Regulation by E2 of
several genes in this category could be detected at earlier
times (peak around 8h after E2 stimulation, Figure 3B),
and was also observed in the presence of CHX at 8h and
at earlier time points (data not shown), conﬁrming their
status as primary target genes. On the other hand, CHX
treatment had an attenuating eﬀect on regulation of other
genes such as the immediate early FOS gene (Figure 4A),
although regulation of the FOS gene was still clearly
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Figure 3. Expression of several genes induced only in the presence
of CHX at 24h is regulated in its absence at earlier times. Q-PCR
analysis of the eﬀects of E2 (25nM) with or without CHX (10mg/ml) as
a function of time on the expression levels of selected genes identiﬁed
through microarray analysis. Data is representative of at least two
independent experiments and is presented as the ratio between +E2
and E2 at all time points. (A) Pattern of expression of a gene stably
induced by estradiol. (B) Patterns of expression of several genes
induced only in the presence of cycloheximide at 24h in the microarray
analysis.
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Figure 2. Cycloheximide-sensitive and resistant E2 target genes in
MCF-7 breast cancer cells. (A) Comparative analysis of regulated genes
in diﬀerent large-scale microarray studies. The number of genes in
common between this study and those described in Carroll et al. (50)
and Rae et al. (71) or unique to each study is indicated. Regulation of
genes common to two diﬀerent studies is convergent (up- or down-
regulation) in 90% of the genes for the overlap between the datasets in
Refs (50) and (71), 96% for the overlap between this study and Ref.
(71), and 92% for the overlap between this study and Ref. (50).
Average overlaps obtained in random simulations performed 1 million
times are identiﬁed by a star and are expressed as percentages of total
genes for pairwise comparisons or as the average number of genes
common to all studies. (B) Identiﬁcation of primary and secondary
estrogen target genes in MCF-7 cells. RNA samples were collected 24h
after treatment of MCF-7 cells with vehicle or 17b-estradiol (25nM).
Cells were pre-treated 1h before E2 stimulation with cycloheximide
(CHX, 10mg/ml). Microarray analysis was performed with four
biological replicates for each condition (see Material and Methods
section). Numbers of genes signiﬁcantly regulated (1.4-fold change
between vehicle and E2 treatments, 5 amplitude of array signals
across all conditions and 0.01P-value based on moderated t-statistics)
are indicated for each category.
82 Nucleic Acids Research, 2008, Vol. 36,No. 1observed in the presence of CHX treatment at 1–2h (data
not shown), as previously reported (72).
Representation of genes involved in cell cycle control,
including cyclins and other cell cycle regulators, is
strikingly diﬀerent in genes regulated in the absence or
presence of CHX (data not shown). This correlates with
the fact that CHX treatment led to loss of progression into
S phase (Supplementary Figure 3). The group of genes
whose induction by E2 was repressed by CHX includes
genes associated with the proliferation signature of breast
cancer cells, such as members of the E2F family of
transcription factors (Figure 4B), of the cell division cycle
(CDC) and minichromosome maintenance (MCM) gene
families (Supplementary Figure 2). Their regulation
reﬂects the proliferative eﬀects of estrogens and the need
for synthesis of cell cycle regulatory proteins that are
controlled between cycles by degradation (73).
ERaparticipates in bothup- and down-regulation ofgene
expression, butEREsare enriched onlyin theflanking
sequencesof up-regulated primary targetgenes
To investigate whether ERa plays a similar role in the
up- and down-regulation of primary target genes, we
selected a sample of ﬁve primary up- and ﬁve down-
regulated target genes and assessed the eﬀect of siRNA-
mediated ERa depletion (Figure 5). Two diﬀerent siRNAs
directed against ERa both markedly reduced levels of
expression of the receptor and levels of cyclin D1
(CCND1) mRNAs (Figure 5A and B), consistent with
their anti-proliferative eﬀects (Figure 1B and C).
Modulation of both up- (Figure 5C) or down-regulated
(Figure 5D) primary estrogen target genes was markedly
attenuated by depletion of ERa. Transfection of siRNAs
directed against GAPDH or LUC on the other hand had
generally little impact on expression of ER target genes in
the absence or presence of estradiol, although we observed
a reproducible eﬀect of the GAPDH siRNA on lowering
TFF1 expression and of the LUC siRNA on increasing
expression of ERBB2, possibly due to eﬀects of these
siRNAs on unknown factors regulating expression of
these genes. Together these results indicate that expression
levels of the receptor are a limiting factor for overall target
gene regulation in MCF-7 cells. These results also suggest
that overexpression of ERa during tumorigenesis likely
plays an important role in potentiating estrogen signaling.
The classical mechanism of action of ERa signaling
involves direct binding to cognate DNA sequences, the
EREs, whose consensus sequence is a palindrome of
PuGGTCA motifs (13,16,17). Surprisingly, there was no
diﬀerence in the percentage of EREs identiﬁed between
groups of up-, down- or non-regulated genes in ZR75 cells
(47). On the other hand, enrichment in EREs was reported
in the promoter sequences of target genes identiﬁed in the
presence of cycloheximide in T47D cells (46); however, the
number of primary target genes identiﬁed was small
(89 genes) and enrichment was assessed only in a 3.5kb
window of regulatory sequences. Here, we compared ERE
frequencies in genes regulated by estradiol in the presence
and/or absence of the protein synthesis inhibitor cyclo-
heximide (CHX) in MCF-7 cells. EREs were identiﬁed at
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Figure 4. Several transcription factors in the E2F family are target
genes of estradiol in MCF-7 breast cancer cells. Q-PCR analysis of the
eﬀects of E2 (25nM) with or without CHX (10mg/ml) as a function of
time on FOS (A) and on E2F transcription factors whose expression
was found to be regulated by E2 in the microarray analysis (B). This
data is representative of at least two independent experiments and is
presented as the ratio between +E2 and E2 at all time points.
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Figure 5. Regulation by estradiol of both up- and down-regulated primary target genes is dependent on ERa. Two siRNAs against ERa and
control siRNAs against GAPDH or Luciferase (LUC) were transiently transfected in MCF-7 cells 48h before stimulation with E2 (25nM) or vehicle
(0.1% ethanol) for 24h, and levels of expression of ERa (A), CCND1 (B), up-regulated (C) or down-regulated (D) primary target genes were
evaluated by using Q-PCR of reverse-transcribed mRNAs.
84 Nucleic Acids Research, 2008, Vol. 36,No. 1variable distances from the transcriptional start sites of
genes using a customized position weight matrix, derived
by compiling binding motifs from the literature and by
symmetrical complementation reﬂecting the palindromic
nature of this site (Figure 6A; note that this matrix yielded
higher enrichment in EREs than the TRANSFAC matrix
in control datasets corresponding to lists of genes with
known EREs or ERa-bound ChIP fragments, data not
shown). Windows of 20kb centered on the transcriptional
start sites (TSS) of target genes were used with diﬀerent
cutoﬀs corresponding to frequencies of sites in the genome
comprised between 0.1 and 2 sites per gene. This approach
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Figure 6. Estrogen response elements are enriched in the vicinity of primary up-regulated genes. (A) Position weight matrix used for identiﬁcation of
putative EREs in the vicinity of target genes. The frequency of nucleotides at each position of the ERE in the matrix is shown. (B) The ratios of the
number of EREs per gene in 20kb windows (10kb) around the transcriptional start sites of regulated genes to the number of EREs per gene in the
same windows of all annotated genes in the human genome are shown for various groups of estrogen target genes. (C) The ratios of EREs found in
ERa-bound chromatin regions (Ref. 50) located within a 20kb window of the regulated genes identiﬁed in our study over EREs found in ERa-bound
chromatin regions at 10kb of all genes in the genome are shown for various groups of estrogen target genes. ChIP regions were standardized to
1kb on either side of the center of the region for this analysis. The numbers of genes in each category analyzed in B and C are indicated in Materials
and Methods section.
Nucleic Acids Research, 2008, Vol. 36, No. 1 85detected a signiﬁcant enrichment in EREs in a test list of
genes found to contain EREs in a genome-wide search for
high-aﬃnity EREs (51) compared to the whole genome
(data not shown). The ratio between the numbers of sites
detected in regulated genes versus all genes in the genome
remained close to one at all cutoﬀs when both up- and
down-regulated genes were considered together, but
increased with higher cutoﬀs in up-regulated genes while
it decreased in down-regulated genes (Figure 6B).
However statistical signiﬁcance (P-value <0.01 and
Z-score >10) was reached only at one point in total
up-regulated genes in this window. On the other hand,
ERE enrichments in E2 target genes up-regulated in the
presence of CHX (+CHX group), but not in its absence
(CHX group), were statistically signiﬁcant. Further
subdivision of the +CHX group into only+CHX and
and+CHX indicated statistically signiﬁcant enrichment
in both the only+CHX group and the and+CHX
groups (Figure 6B). No enrichment was seen in the only–
CHX group, consistent with the interpretation that most
of the genes in this group are secondary target genes.
Similarly, while we did not ﬁnd cutoﬀ-dependent enrich-
ment in EREs in the datasets of up-regulated genes
regulated in Carroll et al. (50) or in Rae et al. (71),
enrichment in EREs can be observed in any intersection
between our set of primary up-regulated genes and these
other sets of regulated genes (Supplementary Figure 4). In
addition, our analysis of another published dataset of
genes regulated in MCF-7 cells by E2 and CHX at 48h
(74) also indicates enrichment in EREs in up-regulated,
but not down-regulated primary targets (Supplementary
Figure 5). Thus, the observation that EREs are enriched in
primary up-regulated target genes is not dataset depen-
dent. Of note, the observation that enrichment was higher
with higher cutoﬀs indicates that sequences closer to the
consensus are more likely to mediate transcriptional
regulation, indicating a statistical relationship between
in vitro aﬃnity and in vivo binding to EREs.
Distribution of EREs in sliding 2.5kb windows with
500bp increments between 25 and +25kb of the TSS
indicates that enrichment of EREs (identiﬁed at a 75%
cutoﬀ) in genes up-regulated in the presence of CHX, but
not in those up-regulated in its absence, can be observed
within 20 to +20kb of the TSS (Figure 7A). Finally,
enrichment in EREs was higher when considering only
ERa-associated chromatin regions (50) found within a
20kb window around the TSS of diﬀerent groups of genes,
reﬂecting the capacity of ChIP to accurately pinpoint the
regulatory regions in target gene ﬂanking sequences
(Figure 6C). However, no enrichment was observed in
the only–CHX group of up-regulated genes even when
considering only ERa-bound fragments (Figure 6C).
Together, these results validate the use of CHX to identify
primary E2 target genes.
Surprisingly, no enrichment but rather a statistically
signiﬁcant depletion in EREs was observed in a 20kb
region around the TSS of genes repressed by estrogens
(Figures 6B and 7B). We examined whether enrichment in
EREs was observed in ERa-associated chromatin regions
(50) found near genes down-regulated in the absence or
presence of CHX (Figure 6C). No enrichment in ERE
sequences was observed in the genes down-regulated either
in the presence or the absence of CHX. This suggests that
binding sites for other transcription factors mediate the
down-regulation of genes by E2 in the presence of CHX
(see also the next section).
To test whether predicted EREs can bind ERa in vivo,
selected regions containing EREs identiﬁed using a 65%
cutoﬀ and present at 25kb of the TSS of target genes
up-regulated in the presence of CHX were ampliﬁed by
PCR after ChIP. Binding of ERa was observed on all
predicted elements with the exception of the ERE with two
mismatches present at +2.3kb of the EGR3 TSS
(Figure 8). Only two of the nine validated elements (the
WISP2 452bp ERE and CA12 6kb ERE) were
detected previously in genome-scale ChIP experiments
(50). The intensity of binding to individual elements did
not necessarily reﬂect their degree of similarity to the
consensus sequence, as one of the strongest sites bound
[at 452bp of the WISP2 TSS, also observed in Ref. (50)],
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Figure 7. Distribution of EREs in a 50kb window around the TSS of
estrogen target genes. (A) Number of EREs per gene identiﬁed at a
75% cutoﬀ rate using the matrix described in Figure 6A in a 2.5kb
sliding window within 50kb of genomic regions centered around the
transcriptional start sites (TSS) of primary (+CHX) or total (CHX)
up-regulated genes. (B) Number of EREs per gene identiﬁed at a 75%
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(+CHX) or total (CHX) down-regulated genes. Note that all
described alternative TSS were considered in this analysis.
86 Nucleic Acids Research, 2008, Vol. 36,No. 1diverges from the consensus ERE by two mismatches.
This may be due to the sequence context of the EREs,
which is likely to aﬀect in vivo aﬃnity through coopera-
tivity with other transcription factors bound close to the
EREs. In addition, the occurrence of several EREs in the
ﬂanking regions of primary target genes suggests potential
cooperativity between EREs for DNA binding and
transcriptional activation through formation of chromatin
loops as described for the GREB1 gene (52).
Binding sites forother transcription factorsare enriched
in up-and down-regulated primary estrogentarget genes
The lack of enrichment of EREs in down-regulated target
genes suggests transcriptional regulation via other mecha-
nisms than ERa binding to EREs. Several transcription
factors have been reported to mediate indirect recruitment
of ERa to DNA via protein–protein interactions [see refs
(15,31–33) for reviews]. In addition, other transcription
factors may also mediate estrogenic regulation via
non-genomic mechanisms (15,34–38). Binding sites for
transcription factors participating in either mechanism
may be enriched in the ﬂanking sequences of primary
regulated genes, while only enrichment in tethering
transcription factors is expected in ERa-associated regions
identiﬁed through ChIP.
To identify transcription factor binding sites enriched in
either up- or down-regulated primary targets, we screened
TRANSFAC matrices for >1.5-fold enrichment in fre-
quencies within 5 or 10kb windows around the TSS of
diﬀerent classes of regulated genes versus all annotated
genes. Due to the variable representation of diﬀerent
transcription factor binding sites in low-complexity
regions, this analysis was performed considering either
whole genomic sequences, sequences without repeated
elements or sequences conserved through evolution.
Enrichments with Z-scores higher than 10 and P-values
<0.01 for at least two diﬀerent cut-oﬀs of the same
matrix were retained as signiﬁcant. This analysis was
performed using either all signiﬁcantly regulated genes
(Supplementary Table 1) or the top 100 regulated genes
(Supplementary Table 2) in each category.
Binding sites enriched in primary up-regulated target
genes (regulated in the presence of CHX) included,
in addition to EREs, sites for AHR/ARNT, AP1,
CCAAT box factors, C/EBP homologous protein
(CHOP), CHX10 homeobox factor, EGR factors, Maf,
GCbox factors and ERE-like sequences with diﬀerent
arrangements of the motifs (Supplementary Tables 1
and 2). On the other hand, binding sites enriched in
primary down-regulated genes include sites for the
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and PAX homeobox factors, EVI1, Ikaros and SRY
transcription factors (Supplementary Tables 1 and 2).
E2Ftranscription factorsare amajorrelay for
transcriptional regulation by estrogens of secondary
targetgenes inMCF-7 cells
No enrichment of EREs was observed in genes regulated
only in the absence of CHX, consistent with their
regulation by other transcription factors. Screening of
TRANSFAC matrices indicated enrichment of E2F-
binding sites in up-regulated secondary targets, as well
as of sites for CCAAT box factors, CREB and Forkhead
(HNF-3B) transcription factors (Supplementary Tables 1
and 2). In addition, sites for AP1, CREB, C/EBP,
CCAAT-box factors, forkhead factors (FOXA, FOXD3,
FOXO4, HFH8), E2F, GATA factors, GC-box factors,
MAZR and PAX factors were enriched in down-regulated
secondary target genes (Supplementary Tables 1 and 2).
Because secondary target genes are enriched in cell
cycle-associated proteins and E2F factors play well-
characterized roles in the regulation of cell proliferation,
we examined more closely the possible contribution of
these factors in the networks of gene regulation by
estrogens. Enrichment in E2F sites within a 10kb
window around transcriptional start sites (5kb) was
strong in genes up-regulated in the absence of CHX
(Figure 9A). It was also observed in genes up-regulated in
the presence of CHX, but not in the only+CHX group,
suggesting that the and+CHX group of regulated genes
was responsible for this over-representation. A similar
enrichment in secondary, but not primary target genes
was observed when restricting the analysis for each group
to genes found to contain E2F-binding sites in their
promoter in ChIP experiments (69), although enrichment
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in down-regulated secondary genes was not observed when
considering all regulated genes (Figure 9, Supplementary
Table 1), but was detected in the top 100 regulated genes
(Supplementary Table 2). Several E2F family members in
addition to E2F1 were regulated by E2, including E2F2,
6, 7 and 8 (Figure 4B), which may explain the prevalence of
the E2F signature in regulated secondary genes.
Genes down-regulated in the absence of CHX were
enriched in binding sites for NF-kB (Supplementary
Table 1), consistent with the repressive role of estrogens
on NF-kB signaling (15,33) although enrichment of these
sites in the absence rather than the presence of CHX was
unexpected. Similarly, binding sites for GATA factors
were enriched in down-regulated secondary target genes
(Supplementary Table 2). Repression of GATA1 tran-
scriptional activity by estrogens has been shown pre-
viously (75,76). More surprisingly in view of the reported
stimulatory eﬀects of estrogens on Sp1- and AP1-mediated
transcription, sites for these transcription factors were
also found enriched in down-regulated secondary target
genes (Supplementary Tables 1 and 2). These results
suggest that AP1 sites may be involved in mediating gene
repression as well as activation (see above for enrichment
in up-regulated primary target genes).
Unexpectedly, c-Myc-binding sites were not found
enriched in any of the target gene categories, whether
considering all sequences, low-complexity sequences or
conserved sequences. This is puzzling in view of the
observation that induction or repression of MYC expres-
sion recapitulates the eﬀects of estrogen and antiestrogens,
respectively, on the cell cycle of ERa-positive breast
cancer cells (77,78). However, comparison of E2 target
genes with those of c-Myc target genes (79) and with genes
regulated by siRNA-mediated suppression of MYC
expression (80) indicates a statistically signiﬁcant enrich-
ment of c-Myc target genes in genes regulated by E2 (data
not shown). C-Myc target genes were distributed in
diﬀerent groups of regulation (up versus down, primary
versus secondary), which may explain the lack of
signiﬁcant enrichment in a speciﬁc group. Poor perfor-
mance of the TRANSFAC matrices in identifying c-Myc-
binding sites could also play a role in the absence of
detected over-representation of these sites in estrogen
target genes. Finally, we also monitored whether c-Myc-
binding sites may be enriched in primary target genes,
consistent with a mechanism of action through non-
genomic activation by estrogens. Indeed, estradiol has
been shown to stabilize the c-Myc protein for at least 12h
through modulation of its phosphorylation status (81).
However, we did not observe signiﬁcant enrichment in this
category of regulated genes either. It remains possible
however that identiﬁcation of E2 target genes at earlier
time points may reveal enrichment in c-Myc-binding sites,
since MYC is one of the earliest known estrogen target
genes (82). Of interest, TIAM1, a repressor of c-Myc that
prevents its apoptotic eﬀects (83), is also a primary
estrogen target gene and may limit the duration of the
induction of some c-Myc target genes.
Together, these data indicate that E2F is a major
mediator of propagation of estrogen signaling in MCF-7
breast cancer cells for both up- and down-regulated
secondary target genes, and suggest that AP1 may play
a role in the down-regulation of secondary target genes.
DISCUSSION
Microarray analyses of estrogen target genes have been
performed previously in various ERa-positive cell lines.
However, only a limited number of genes have been found
to be commonly regulated so far (46,71). Although this
may be due to intrinsic diﬀerences between responses in
these cells (71), variability between studies may also take
place due to diﬀerences in cell culture conditions,
microarray platform and selection criteria for signiﬁcantly
regulated genes. In this study, we chose to perform
microarray analysis in 0.5% charcoal-treated serum, to
minimize unstimulated levels of cellular growth; other
studies were performed in 5% (45,50) or 10% serum
(70,71). Our control was provided by cells treated with
vehicle for the same time as with E2, whereas other studies
have compared induction by E2 at diﬀerent times with the
absence of treatment at time 0 (50,70,71). We used the
HG-U133 2.0 Plus GeneChips, while most other studies
used anterior versions of Aﬀymetrix GeneChips
(45,70,71). Finally, we used a combination of three
parameters, i.e. fold-change, average expression levels
and P-value, to rank regulated genes, with set minima for
each parameter (see Materials and Methods section). We
identiﬁed 2144 signiﬁcantly regulated genes, of which
more than 50% overlapped with at least one of the two
previous large-scale microarray studies also performed in
MCF-7 cells (50,71). As we did not observe a higher
overlap between sets of regulated genes described in these
two other studies, we speculate that this partial overlap
results from a combination of diﬀerences in experimental
design and/or microarray platforms, rather than from the
use of cycloheximide speciﬁc to our study.
While enrichment in diﬀerent transcription factors has
been reported in E2 targets in diﬀerent studies (47,70),
only one study based on microarray analysis exclusively
has reported enrichment in EREs in the promoter
sequences (3 to +0.5kb) of 89 genes identiﬁed as
primary targets based on lack of eﬀect of cycloheximide
on regulation (46). Here, we identiﬁed 780 genes
signiﬁcantly regulated by E2 in the presence of CHX
(544 up-regulated and 236 down-regulated genes). Overlap
with genes regulated in the absence of CHX was partial.
This can be explained in part by the fact that regulation of
several genes found signiﬁcantly modulated in the
presence of CHX was also observed in its absence at
earlier times, but became non-signiﬁcant at 24h. Genes in
this category may include G1 phase-speciﬁc genes, as
cycloheximide inhibited the increase in S phase induced
by E2. In addition, possible inhibition by cycloheximide of
negative feedback regulatory loops may also result in
increased gene regulation at 24h. Because CHX has major
eﬀects on gene expression (more than 4000 genes were
eitherup-ordown-regulated inourstudy,datanotshown),
it remains possible that CHX treatment may mask regu-
lation of some primary target genes. However, we did not
Nucleic Acids Research, 2008, Vol. 36, No. 1 89ﬁnd that CHX treatment had a signiﬁcant global eﬀect on
expression of the group of genes induced only in the
absence of CHX (Supplementary Figure 1).
Enrichment in EREs was observed only in genes
up-regulated in the presence of CHX, including both
genes regulated in the absence and presence of CHX and
those regulated in the presence of CHX only. These
observations validate the characterization of these genes
as primary E2 targets, and explain the lack of reported
enrichment of EREs in previous microarray studies that
did not discriminate between primary and secondary
target genes. Enrichment in EREs in genes up-regulated in
the presence of CHX was detectable in a +/20kb
window centered on the TSS of regulated genes, consistent
with a role of distal EREs in transcriptional regulation.
This enrichment is not data-dependent, as we observed
similar results using the subsets of our primary target
genes that are in common with other microarray analyses,
or using a dataset of 130 primary estrogen target genes
regulated at 48h in MCF-7 cells (74) (Supplementary
Figures 4 and 5).
Regulatory sequences of up-regulated primary target
genes often contained several EREs in a 20kb window
around the TSS. For instance, two functional EREs were
validated in ChIP experiments in several selected primary
target genes (CDH26, WISP2, CA12). Of interest, only
two of the EREs validated in ChIP assays were previously
reported in genome-wide ChIP-on-chip studies (50), likely
due to the stringency used in this study to minimize false
positive rates. While no correlation between identity with
the consensus sequence and apparent strength of binding
was observed for individual binding sites, general enrich-
ment in EREs were more pronounced for sequences more
similar to the consensus sequence, indicating that
sequences that are high-aﬃnity binding sites in vitro
have a higher statistical chance of mediating E2 regulation
in vivo, although the genomic context of the response
element inﬂuences aﬃnity at the individual level. The
presence of multiple EREs in the vicinity of regulated
genes may result in the formation of multiple chromatin
loops associating these EREs and the TSS of regulated
primary target genes as previously described (52).
Intriguingly, genes down-regulated in the presence of
CHX were not enriched in EREs. Rather, a statistically
signiﬁcant depletion in EREs was observed. We also
observed a lack of enrichment in EREs in ERa-bound
chromatin regions located in the vicinity of genes
repressed by E2 in Ref. (50). This may indicate that the
presence of EREs in the ﬂanking regions of genes confers
a likelihood of positive rather than negative regulation.
However, down-regulation of gene expression via binding
of ERa to strategically positioned EREs remains possible,
as EREs are still found, although less represented, in the
vicinity of repressed primary E2 target genes. Similarly to
what was observed in our dataset, we ﬁnd that EREs were
not enriched in down-regulated primary genes identiﬁed
after 48h stimulation with E2 (74). However, it will be of
interest in the future to assess the frequency of EREs in
the ﬂanking regions of sets of primary genes down-
regulated at other, including earlier, time points.
Binding sites for other transcription factors were
enriched in primary up- and down-regulated genes.
Binding sites enriched in down-regulated primary target
genes have not before been associated with E2 action, but
include two zinc ﬁnger transcription factors participating
in corepressor complexes, EVI1 (84) and Ikaros (IKZF1)
(85). On the other hand, binding sites enriched in
up-regulated target genes include AP1, which have been
previously demonstrated to mediate tethering of ERs. In
addition, the ARNT gene encodes a protein that forms a
complex with the ligand-bound Ah receptor (AhR).
Activated AhR/Arnt was shown to act as a coactivator
of estrogen receptor-mediated signaling, while ERa-AhR/
Arnt protein–protein interactions mediate estradiol-
dependent transrepression of dioxin-inducible gene tran-
scription (86,87). Enrichment of AhR/Arnt sites in
primary up-regulated genes suggests that AhR/Arnt-ERa
complexes also mediate estradiol-dependent up-regulation
of some AhR/Arnt target genes. Finally, EGR genes are,
like AP1 components JUN and FOS, immediate early
genes activated by a variety of signaling molecules (88,89).
It is possible that these factors may contribute to gene
regulation via non-genomic activation by estrogen, as
suggested before (90).
Sites enriched in primary target genes may mediate
regulation either through tethering of ERa or through
non-genomic eﬀects. Comparison with sites enriched in
ERa-bound chromatin regions may help to discriminate
between the two mechanisms, since only transcription
factors mediating ERa recruitment via tethering should
have sites within ChIP fragments. Enrichment of AP1,
Maf, C/EBP, GATA and SOX-binding sites in ERa-
bound chromatin regions may thus indicate recruitment of
ERa to these sites. However, choice of background
datasets is more complicated in the case of ChIP-on-chip
data, and may aﬀect site enrichment. For instance,
enrichment in Egr or Sp1 factors in ERa-associated
ChIP fragments was dependent on the choice of the
reference background (promoter sequences versus ﬂank-
ing sequences of ChIP regions, data not shown). It should
also be noted that, since cooperativity between ERa–ERE
complexes and transcription factors bound to the same
promoter may result in indirect association of ERa with
these transcription factors through chromatin looping,
low levels of enrichment of sites for a variety of
transcription factors may be expected in ERa-associated
regions.
Several other transcription factors were found enriched
in secondary target genes. Surprisingly, NF-kB, AP1,
GATA and Sp1 sites were all enriched in secondary down-
regulated genes. This observation is consistent with the
previous report that AP1 sites were present in ER-
associated chromatin regions found close to genes
repressed by E2at late time points, this regulation being
dependent on the induction of a co-repressor component
such as the NRIP1 ERa co-repressor (50). It will be of
interest to determine whether NRIP1 induction is also
required for regulation of genes repressed by E2 and
containing binding sites for NF-kB, GATA or Sp1 sites.
One of the most enriched binding sites in up-regulated
secondary target genes is that for E2F transcription factors.
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well-known role of this family of transcription factors in
the control of cell cycle, with known targets including
several minichromosome maintenance (MCM) genes,
which are essential for cell cycling due to the function of
their products as replication-licensing factors (91). Other
common E2F and ER targets involved in cell cycle
regulation include the CDC6 and CDC25A cell division
cycle genes, the PCNA and POLA2 genes, the replication
factor C subunit RFC4, the structural maintenance of
chromosome 2 (SMC2) and the protein regulator of
cytokinesis one (PRC1) genes. Notably, we observed that
not only E2F1, but also E2F2, E2F7 and E2F8 transcrip-
tion factors were up-regulated by E2. E2F7 and E2F8 can
repress E2F-activated transcription (92,93). E2F6 is also
an inhibitory E2F family member (94,95) that can repress
c-Myc target genes (96), but its induction proﬁle was
diﬀerent from that of other E2F factors. The regulation
of this gene may be explained by the fact that it is
transcribed in the opposite direction from GREB1,
a primary E2 target gene containing three consensus
EREs in its ﬂanking sequences (51, 52). Additional studies
will be necessary to investigate the mechanisms of the
transcriptional regulation of E2F family members by E2,
and their exact individual roles in gene expression and cell
cycle regulation by E2.
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